Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

ConclusionsHuMax-IL8 is safe and well-tolerated. Ongoing studies are evaluating the combination of IL-8 blockade and other immunotherapies.Trial registrationNCTN, NCT02536469. Registered 23 August 2015,https://clinicaltrials.gov/ct2/show/NCT02536469?term=NCT02536469&rank=1.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research